Hemodialysis acutely altered interferongamma release assay test result and immune cell profile

Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/9205

Full metadata record

DC Field	Value	Language
dc.contributor.author	Utami Putri, Denise	-
dc.contributor.author	Chen, Chia-Ling	-
dc.contributor.author	-Hui Wang, Cheng	-
dc.contributor.author	Mou Sue, Yuh-	-
dc.contributor.author	Tseng, Po-Chun	-
dc.contributor.author	-Feng Lin, Chiou	-
dc.date.accessioned	2024-12-18T02:42:53Z	-
dc.date.available	2024-12-18T02:42:53Z	-
dc.date.issued	2022-04-01	-
dc.identifier.issn	1684-1182	-
dc.identifier.uri	http://localhost:8080/xmlui/handle/123456789/9205	-
dc.description.abstract	Abstract Patients receiving hemodialysis (HD) are at risk of TB development. IGRA-positive patients showed significant decrease in quantitative IGRA result with alterations inCD3þCD4þCD45ROþ, NK cell, and monocyte subsets immediately upon HD procedure. Our result suggested that the timing of IGRA testing is crucial in end-stage renal disease population.	en_US
dc.language.iso	en	en_US
dc.publisher	Elsevier Taiwan LLC	en_US
dc.subject	Interferon gammarelease assay;	en_US
dc.subject	End stage renal disease;	en_US
dc.subject	Hemodialysis;	en_US
dc.subject	IGRA variability;	en_US
dc.subject	Peripheral immune profile	en_US
dc.title	Hemodialysis acutely altered interferongamma release assay test result and immune cell profile	en_US
dc.type	Article	en_US
Appears in Collections:	VOL 55 NO 2 2022

Files in This Item:

File	Description	Size	Format
332-335.pdf		666.79 kB	Adobe PDF	View/Open

DSpace JSPUI